Alpha Cognition Inc. 8-K

What Happened
Alpha Cognition Inc. announced on Form 8-K that its board appointed Bethany Sensenig as a director effective April 15, 2026. Ms. Sensenig brings extensive finance and operations experience in the biopharma sector, most recently serving as CFO and Head of Operations at Radius Health, Inc. (May 2024 – April 2026).

Key Details

• Appointment effective April 15, 2026; disclosed in an 8-K filed April 20, 2026.
• Professional background: CFO & Head of Operations at Radius Health (May 2024–Apr 2026); CFO and Interim CEO at 9 Meters Biopharma (Jan 2022–July 2023); CFO & Head of U.S. Operations at Minovia Therapeutics (June 2019–Jan 2022); 13 years at Biogen, last as VP of Finance and Commercial Operations.
• Public company board experience: currently a director at Supernus Pharmaceuticals (SUPN) and KalVista Pharmaceuticals (KALV).
• Director compensation: received initial equity grants per the company’s non-employee director policy — 5,489 restricted stock units and 6,991 stock options with an exercise price of $6.65; both awards vest one year after grant.
• No family relationships or related-party transactions were reported in connection with the appointment.

Why It Matters
This adds a senior finance and operations executive with M&A, financing and commercial experience to Alpha Cognition’s board, which may strengthen governance and financial oversight. The filing also discloses the size and terms of the equity award (RSUs and options, one-year vest), a concrete, non-cash cost to the company that could modestly increase share-based compensation outstanding. No related-party concerns were reported.